Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
PCI and PACT Host AI Event for Philly Tech Week
PCI and the Philadelphia Alliance for Capital and Technologies (PACT) jointly presented a recent event called “AI Nexus: Shaping Tomorrow’s Intelligence."
A Rare Patient Mutation May Help Lead to More Effective Treatments for Genetic Bone Disease
Davis' relatively benign symptomology is attributed to low levels of the inflammatory protein MMP-9, which seems to prevent the characteristic abnormal bone formation.
Penn Researchers Create Novel mRNA-based Avian Flu Vaccine
Penn Medicine researchers have developed an mRNA vaccine for the H5N1 avian flu using techniques similar to those enabling mRNA-based COVID-19 vaccines.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Achieves FDA Clearance for Phase I Trial of its CAR T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iECURE Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
New Method Created for Improving the Resolution of Routine Medical Images
This novel method improves resolution of routine low resolution clinical images, saves MR scan time, and reduces radiation dosage levels for CT scanning.